Plaque Psoriasis Phase 3 Study CP-690,550 Report for Patients Like You

Filter by:

All
Start typing to see suggestions

patients

Home > Community Treatment Reports and Side Effects > Plaque Psoriasis Phase 3 Study CP-690,550 Treatment Report

You appear to have JavaScript disabled in your browser. PatientsLikeMe relies on JavaScript and Cookies to deliver the best possible experience to you. How do I enable JavaScript?

What is Plaque Psoriasis Phase 3 Study CP-690,550?

NCT01186744 is a randomized, mixed-blind, parallel-group treatment withdrawal and re-treatment study in subjects with moderate to severe chronic plaque psoriasis. The drug CP-690,550 is also known as tofacitinib (formerly tasocitinib). Another study name is A3921111

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose	# of patients	# of patients with evaluations Efficacy	Major	Moderate	Slight	None	Can’t tell
Psoriatic plaques (scaly patches)	1	0

See 1 patient currently using Plaque Psoriasis Phase 3 Study CP-690,550

Mouse over the table for more information

Reported Schedules

	20 mg daily
	1

Report created on May 28, 2012.